Solid Tumor Program

Solid tumors account for approximately 40 percent of pediatric cancers and 68 percent of adolescent and young adult cancers. Our solid tumor medical team specializes in treating:

Wilms and other kidney related tumors
Hepatoblastoma and other liver tumors
Sarcomas including rhabdomyosarcomas and other soft tissue sarcomas
Germ cell tumors
Retinoblastoma
Nasopharyngeal carcinoma
Melanoma
Adrenocortical carcinoma
Rare tumors

Our expertise also includes treating non-malignant conditions such as Langerhans cell histiocytosis, histiocytic and hemophagocytic lymphohistiocytosis (HLH) disorders, fibromatosis and benign tumors that may require surgery and surveillance.

Team approach

Our team includes oncologists, pediatric surgeons, radiation oncologists, pathologists, interventional radiologists and psychosocial support staff with extensive experience with all tumor types. We have an excellent research team, clinical research nurse coordinator and team nurses to help navigate patients and their families through diagnosis and treatment and through off-therapy follow-up and survivorship programs.

Working together

The treatment of solid tumors may require a range of therapies, including surgery, radiation therapy, chemotherapy, stem cell therapy, biologic or targeted therapies, or a combination of these treatment modalities. Because of this, we work very closely with doctors and medical teams in many different specialties. This helps to ensure that your child recieves the most complete care possible. For children with a genetic predisposition to cancer, we also work with geneticists and genetic counselors when needed, to provide care and routine exams and studies.

In treating pediatric Solid Tumors, our goal is to provide family-centered care utilizing the most advanced treatment, superior research and family preference to obtain the best chances for cures. As active members of Children’s Oncology Group and through additional collaborations with expert oncology centers including St. Jude Children’s Research Hospital, Texas Children’s, and others throughout the country, we offer our patients the most promising evidence-based treatments and research trials available.

Active solid tumor research studies

A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE).

Primary Investigator: Kelly L. Vallance

IRB ID: 2020-014 (OPEN)

Study Information
Request Information
A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors

Primary Investigator: Kelly L. Vallance

IRB ID: 2017-002 (OPEN)

Study Information
Request Information
A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors

Primary Investigator: Kelly L. Vallance

IRB ID: 2019-063 (OPEN)

Study Information
Request Information
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Primary Investigator: Kelly L. Vallance

IRB ID: 2017-030 (OPEN)

Study Information
Request Information
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

Primary Investigator: Kelly L. Vallance

IRB ID: 2019-101 (OPEN)

Study Information
Request Information
AREN1921

Primary Investigator: Kelly L. Vallance

IRB ID: 2020-097 (OPEN)

Request Information
Clinical, Radiologic, And Molecular Characteristics Of Anaplastic Pleomorphic Xanthoastrocytomas

Primary Investigator: Sibo Zhao

IRB ID: 2020-063 (OPEN)

Request Information
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma

Primary Investigator: Donald Beam

IRB ID: 2018-028 (OPEN)

Study Information
Request Information
Multi-center Phase III, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolimide as a Second-Line Regimen for Ewing's Sarcoma

Primary Investigator: Anish K. Ray

IRB ID: 2019-005 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 study of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR alterations

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-008 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 study of LOXO-101 (Larotrectinib) in patients with tumors harboring NTRK fusions.

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-006 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 study of Olaparib in patients with tumors harboring defects in DNA damage repair genes

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-007 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 study of Tazemetostat in patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-005 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 study of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-003 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 study of LY3023414 in patients with solid tumors

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-009 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 study of Selumetinib in patients with tumors harboring activating MAPK pathway mutations

Primary Investigator: Kelly L. Vallance

IRB ID: 2017-066 (TEMPORARILY CLOSED TO ACCRUAL)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 study of Vemurafenib in patients with tumors harboring BRAF V600 mutations

Primary Investigator: Kelly L. Vallance

IRB ID: 2018-004 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Primary Investigator: Kelly L. Vallance

IRB ID: 2017-065 (OPEN)

Study Information
Request Information
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)-Phase 2 Subprotocol Of BVD-523FB (Ulixertinib) In Patients With Tumors Harboring Activating Mapk Pathway Mutations

Primary Investigator: Kelly L. Vallance

IRB ID: 2019-102 (OPEN)

Study Information
Request Information

We are here to help.

If your child has been diagnosed, you probably have lots of questions. We can help. If you would like to schedule an appointment, refer a patient or speak to our staff, please call our offices at 682-885-4007.